Cadrenal Therapeutics (CVKD) Earnings Date, Estimates & Call Transcripts $16.68 +0.12 (+0.72%) (As of 11:46 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cadrenal Therapeutics Latest Earnings SummaryUpcoming Q3 Earnings DateMar. 10EstimatedActual EPS (Aug. 7) -$33.75 Beat By $251.85 Consensus EPS (Aug. 7) -$285.60 Cadrenal Therapeutics posted Q2 2024 earnings on August 7, 2024, reporting an EPS of -$33.75, which beat analysts' consensus estimates of -$285.60 by $251.85. With a trailing EPS of -$6.68, Cadrenal Therapeutics' earnings are expected to grow next year, from ($7.92) to ($3.81) per share. CVKD Upcoming EarningsCadrenal Therapeutics' next earnings date is estimated for Monday, March 10, 2025, based off prior year's reporting schedules. Get Cadrenal Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCVKD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CVKD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Cadrenal Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.09-$0.09-$0.09Q2 20241-$0.12-$0.12-$0.12Q3 20242-$2.18-$0.16-$1.17Q4 20242-$2.18-$0.17-$1.18FY 20246-$4.57-$0.54-$2.56Q1 20251-$2.15-$2.15-$2.15Q2 20251-$1.26-$1.26-$1.26Q3 20251-$1.39-$1.39-$1.39Q4 20251-$1.42-$1.42-$1.42FY 20254($6.22)($6.22)($6.22) Cadrenal Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/10/2025(Estimated)------- 8/7/2024Q2 2024-$285.60-$33.75+$251.85-$2.25--5/9/2024Q1 2024-$0.07-$0.10 -$0.03-$0.10-- 3/11/2024Q4 2023-$0.09-$0.05+$0.04-$0.05-- 11/9/2023Q3 2023--$0.07 -$0.07-$0.07-- 8/10/2023Q2 2023--$0.09 -$0.09-$0.09-- 5/10/2023Q1 2023--$0.41 -$0.41-$0.34-- Get the Latest News and Ratings for CVKD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Cadrenal Therapeutics Earnings - Frequently Asked Questions When is Cadrenal Therapeutics's earnings date? Cadrenal Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates. Learn more on CVKD's earnings history. Did Cadrenal Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cadrenal Therapeutics (NASDAQ:CVKD) reported ($33.75) earnings per share (EPS) to beat the analysts' consensus estimate of ($285.60) by $251.85. Learn more on analysts' earnings estimate vs. CVKD's actual earnings. How much profit does Cadrenal Therapeutics generate each year? Cadrenal Therapeutics (NASDAQ:CVKD) has a recorded net income of -$8.36 million. CVKD has generated -$6.68 earnings per share over the last four quarters. What is Cadrenal Therapeutics's EPS forecast for next year? Cadrenal Therapeutics's earnings are expected to grow from ($7.92) per share to ($3.81) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Citius Pharmaceuticals Earnings Quince Therapeutics Earnings ZIVO Bioscience Earnings IO Biotech Earnings AlloVir Earnings Spero Therapeutics Earnings Syros Pharmaceuticals Earnings VolitionRx Earnings Vor Biopharma Earnings Prelude Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run DeFi Coin on Verge of Breakout! (Ad)The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! This page (NASDAQ:CVKD) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
